Vertex Pharmaceuticals INC / Ma Form 4 insider transactions

Amit Sachdev, EVP Chief Patient & External Affairs Officer at Vertex Pharmaceuticals, reported the disposal of 3,703 shares of common stock to cover tax obligations.

Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals, disposed of 14,079 shares of common stock on February 26, 2025, to cover tax obligations.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, disposed of 4,962 shares of common stock on February 26, 2025, to cover tax obligations.

Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer of Vertex Pharmaceuticals, sold 2,650 shares of common stock at $475.34 per share on February 27, 2025, according to a Form 4 filing.

Stuart A. Arbuckle, EVP and COO of Vertex Pharmaceuticals, reported the disposal of 7,071 shares of common stock to cover tax obligations.

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, disposed of 1,241 shares of common stock on February 26, 2025, to cover tax obligations.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the disposition of shares under a pre-arranged trading plan.

Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, disposed of 3,310 shares of common stock on February 24, 2025, to cover tax obligations.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, reports the disposition and acquisition of company stock.

EVP, Chief Patient & External Affairs Officer of Vertex Pharmaceuticals, Amit Sachdev, reports disposition of shares to cover tax obligations.

Reshma Kewalramani, CEO of Vertex Pharmaceuticals, disposed of 9,386 shares of common stock on February 24, 2025, to cover tax obligations.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reported the disposal of 3,310 shares of common stock to cover tax obligations.

Edward Morrow Atkinson III, an executive at Vertex Pharmaceuticals, sold 1,767 shares of common stock at $480.95 per share on February 25, 2025, according to a Form 4 filing.

Stuart A. Arbuckle, EVP, COO of Vertex Pharmaceuticals, reports the disposal of 4,716 shares of common stock to cover tax obligations.

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the disposition of shares of common stock on February 24 and 25, 2025.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the acquisition and disposal of company stock, including transactions made under a pre-arranged trading plan.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, sold 1,111 shares of common stock on February 20, 2025, at a price of $480 per share, according to a Form 4 filing with the SEC.

Charles Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, disposed of 2,293 shares of common stock on February 14, 2025, to cover tax obligations.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Amit Sachdev, EVP Chief Patient & External Affairs Officer at Vertex Pharmaceuticals, reported disposing of 2,139 shares of common stock to cover tax obligations.

Jeffrey M. Leiden, Executive Chairman of Vertex Pharmaceuticals, disposed of shares to cover tax obligations arising from vested restricted stock units.

Reshma Kewalramani, CEO of Vertex Pharmaceuticals, disposed of 6,553 shares of common stock on February 14, 2025, to cover tax obligations.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reported disposing of 1,912 shares of common stock on February 14, 2025.

EVP and Chief Legal Officer of Vertex Pharmaceuticals, Jonathan Biller, reports the disposition of common stock, including a sale to cover tax obligations.

EVP Edward Morrow Atkinson III sold 1,529 shares of Vertex Pharmaceuticals stock on February 14, 2025, to cover tax obligations.

Stuart A. Arbuckle, EVP, COO of Vertex Pharmaceuticals, reports disposing of 2,724 shares of common stock to cover tax obligations.

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the disposition of shares to cover tax obligations and a sale under a pre-arranged trading plan.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reported disposing of 2,293 shares of common stock on February 14, 2025, to cover tax obligations.

Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, reports acquiring 6,655 shares of common stock on February 12, 2025, through a restricted stock unit award.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, acquired 6,211 shares of common stock through a restricted stock unit award.